↑ Rising
Business
Introducing Fierce Biotech's 2026 Fierce 15
Fierce Biotech’s new “Fierce 15” list spotlights four private biotech innovators, signaling fresh investment focus for 2026
Infinimmune
2 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Infinimmune
This hub groups 2 separate news trends connected to Infinimmune, spanning August 11, 2026 through October 5, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 14 article observations and 14 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Regeneron backs $75M series A for antibody upstart Infinimmune
Alameda-based biotech Infinimmune has secured $75 million in Series A funding to advance its antibody pipeline for atopic dermatitis and inflammatory diseases.